Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
You are here: Home / 2014 / Archives for March 2014

Archives for March 2014

GMiA welcomes the release of the Pharmaceutical Patent Review

March 25, 2014 By Emilia

21 March 2014.

Members of the generic medicines industry sector welcomes the release by IP Australia of the Pharmaceutical Patent Review.

GMiA supports a well balanced pharmaceutical patent system that adequately addresses the rights of originator and generic pharmaceutical companies.  Patents are effective and necessary tools for promoting innovation. GMiA members are not anti-patent.

However, the current Australian system for pharmaceutical patents is not effectively balancing the objectives of “securing timely access to competitively priced pharmaceuticals, fostering innovation and supporting employment in research and industry”[1] as stated in the aim of the Pharmaceutical Patents Review carried out last year.

Some originator pharmaceutical companies are using the patent system to inappropriately delay the supply of generic medicines in Australia.

This imbalance is significantly costing Australia.  Delaying generic medicine entry onto the market means that the Government pays more for longer.  The delay is caused by a combination of strategies employed by originator companies and deficiencies in the Australian legal system.

The Pharmaceutical Patent Review has performed an in-depth review of this issue and the findings of this Panel are welcomed by GMiA.

The publication of the Pharmaceutical Patent Review is an important step in addressing inappropriate delay of the supply of generic medicines in Australia.

The report can be found at  https://www.ipaustralia.gov.au/pdfs/2013-05-27_PPR_Final_Report.pdf

 ENDS

Filed Under: Latest news, News 2014

GMiA calls on government to think before irreversible damage occurs to the generic medicines industry

March 13, 2014 By Emilia

13 March 2014.

Today, at the Annual Professional Pharmacy (APP) conference attended by members of the National Pharmacy Guild of Australia, Mr Mark Crotty, Chairman of the Generic Medicines Industry Association (GMiA), called on government to think before irreversible damage occurs to the generic medicines industry in Australia.

Mr Crotty highlighted, “PBS reform is delivering more savings than expected and to avoid inflicting irreversible damage to the generic medicines industry, it is important that there are no more damaging price cuts to generic medicines”.

These unforecasted and unplanned savings are most damaging to the generic medicines sector and disproportionately damage the generic medicines industry model placing at risk a viable generic medicines industry and patient access to medicines. Policy changes are urgently required.

It is imperative that if Australians want a best practice PBS, we should not aim for the ‘cheapest’ scheme or cherry-pick elements from other countries. A best practice PBS provides a stable industry with fair remuneration from the PBS and is an essential foundation for the entire medicines industry in Australia.

-Ends-

Filed Under: Latest news, News 2014

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Mylan
Mylan
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
iqvia
iqvia
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

GBMA welcomes Fresenius Kabi Australia

October 4, 2019

4 October 2019 Canberra, ACT Canberra: Australia’s peak body representing generic and biosimilar manufacturers, the Generic and … More...

Federal Health Minister, Greg Hunt MP encourages healthcare sector to embrace biosimilar medicines.

October 2, 2019

2 October 2019 Doctors, pharmacists, medical researchers, and hospital leaders attend 'Your … More...

GBMA welcomes new appointment to the Board

September 30, 2019

30 September 2019 Canberra, ACT The nation’s peak body for generic and biosimilar … More…

© 2019 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us